# Myomo, Inc.


**MYO**

NYSE; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001369290

# B/C

**on the B/C boundary of 367 graded peers in healthcare**

rank 148 of 367; percentile 40.2; sampling error 2.5 points; lower is stronger




**B/C, the elk**




| Scoreboard | |
|---|---|
| **Profitability** | C<br>percentile 47.7 |
| **Solvency** | C/D<br>percentile 62.1 |
| **Growth and financing** | B<br>percentile 25.9 |
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $38.6M |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered; fortress balance sheet |
| **Inputs computable** | 9 of 14 |
| **Graded from** | filings received through Apr 29, 2026<br>201 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026 |
| **Last close** | $1.23<br>2026-11-13; market equity $49.3M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Mar 9, 2026*

We are a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. We develop and market the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis. The orthosis is a rigid brace used for the purpose of supporting a patient's weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. It is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 47.7** | | | | | | |
| Gross profitability | 69.6% | 32.3% | | 12.1 | 365 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |

*a prior annual debt, equity, and cash observation is required*

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| Accruals ratio | (2.6%) | (6.6%) | 73.4 | 799 | 2025-12-31 |
| Gross margin stability, five years | 3.3 pts | 2.8 pts | 57.7 | 242 | 2025-12-31 |
| **Solvency, sleeve percentile 62.1** | | | | | |
| Twelve-month failure probability | 0.37% | 0.08% | 73.0 | 245 | 2026-09-30 |
| Altman Z double-prime | (8.82) | (0.31) | 59.8 | 743 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *EBITDA must exceed $100,000* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 3.30x | 2.96x | 53.5 | 825 | 2025-12-31 |
| **Growth and financing, sleeve percentile 25.9** | | | | | |
| Revenue growth, three-year compound | 38.1% | 10.1% | 17.8 | 411 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 11.0% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *pretax income must exceed the validity floor and imply a 0%-100% tax rate* | | | | | |
| Asset growth, three years | 56.1% | 2.3% | 6.8 | 693 | 2025-12-31 |
| Net share issuance, one year | 12.0% | 2.4% | 53.2 | 627 | 2026-03-02 |


## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Fortress balance sheet | cash minus debt is 2,909,872 USD; Altman Z is not used |

## Among 367 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 143 | LifeStance Health Group, Inc. (LFST) | 38.8 | B/C | |
| 144 | CorMedix Inc. (CRMD) | 39.1 | B/C | |
| 145 | National Healthcare Corp. (NHC) | 39.3 | B/C | fortress balance sheet |
| 146 | Biocryst Pharmaceuticals Inc. (BCRX) | 39.6 | B/C | distress, fortress balance sheet |
| 147 | Celldex Therapeutics, Inc. (CLDX) | 39.9 | B/C | short runway |
| 148 | Myomo, Inc. (MYO) | 40.2 | B/C | fortress balance sheet |
| 149 | Lensar, Inc. (LNSR) | 40.4 | B/C | |
| 150 | Pacira BioSciences, Inc. (PCRX) | 40.7 | B/C | |
| 151 | Medtronic plc (MDT) | 41.0 | B/C | |
| 152 | Lifevantage Corp. (LFVN) | 41.3 | B/C | |
| 153 | Community Health Systems Inc. (CYH) | 41.5 | B/C | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

## What the price implies

*at the 2026-11-13 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 68.5% | (1.5%) | 82 |
| Distance from 52-week high | (33.9%) | (32.0%) | 46 |
| EBIT to enterprise value | (28.9%) | (1.8%) | 22 |
| Free cash flow yield | (33.0%) | (1.0%) | 19 |
| Book value to price | 0.06 | 0.29 | 18 |
| Sales to price | 0.83 | 0.29 | 79 |
| Composite equity issuance, five years | 197.2% | 19.1% | 88 |
| Relative strength against the sector, log excess return | 0.35 | (0.18) | 82 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | pass |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $11.1M |
| Operating cash flow, four quarters | -$6.6M |
| Months of runway | 20.2 |
| Days since last periodic filing | 7 (10-Q received Nov 9, 2026) |
| Median daily dollar volume, 63 sessions | $434,825 |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | gross profit | us-gaap:GrossProfit | $26.9M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 2 | assets | us-gaap:Assets | $38.6M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 3 | operating income | us-gaap:OperatingIncomeLoss | -$14.4M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 4 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$15.1M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 5 | income tax | us-gaap:IncomeTaxExpenseBenefit | $504,532 | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 6 | total debt | us-gaap:LongTermDebt | $11.2M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 7 | book equity | us-gaap:StockholdersEquity | $11.4M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 8 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $14.1M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 9 | net income | us-gaap:NetIncomeLoss | -$15.6M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 10 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$14.5M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 11 | assets | us-gaap:Assets | $42.2M | 2024-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 12 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $40.9M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 13 | gross profit | us-gaap:GrossProfit | $23.2M | 2024-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 14 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $32.6M | 2024-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 15 | gross profit | us-gaap:GrossProfit | $13.2M | 2023-12-31 | 2025-03-10 | 10-K | 25-036349 |
| 16 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $19.2M | 2023-12-31 | 2025-03-10 | 10-K | 25-036349 |
| 17 | gross profit | us-gaap:GrossProfit | $10.3M | 2022-12-31 | 2024-03-08 | 10-K | 24-028326 |
| 18 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $15.6M | 2022-12-31 | 2024-03-08 | 10-K | 24-028326 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 19 | gross profit | us-gaap:GrossProfit | $10.3M | 2021-12-31 | 2023-03-13 | 10-K | 23-007560 |
| 20 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $13.9M | 2021-12-31 | 2023-03-13 | 10-K | 23-007560 |
| 21 | current assets | us-gaap:AssetsCurrent | $27.6M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 22 | current liabilities | us-gaap:LiabilitiesCurrent | $8.3M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 23 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$118.7M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 24 | liabilities | us-gaap:Liabilities | $27.2M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 25 | depreciation amortization | us-gaap:Depreciation | $859,354 | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 26 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.7M | 2025-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 27 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$3.3M | 2024-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 28 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $1.4M | 2024-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 29 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$6.2M | 2023-12-31 | 2025-03-10 | 10-K | 25-036349 |
| 30 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $145,816 | 2023-12-31 | 2025-03-10 | 10-K | 25-036349 |
| 31 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$10.2M | 2022-12-31 | 2024-03-08 | 10-K | 24-028326 |
| 32 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $111,793 | 2022-12-31 | 2024-03-08 | 10-K | 24-028326 |
| 33 | current assets | us-gaap:AssetsCurrent | $32.8M | 2024-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 34 | current liabilities | us-gaap:LiabilitiesCurrent | $10.2M | 2024-12-31 | 2026-03-09 | 10-K | 26-098531 |
| 35 | assets | us-gaap:Assets | $14.6M | 2023-12-31 | 2025-03-10 | 10-K | 25-036349 |
| 36 | assets | us-gaap:Assets | $10.2M | 2022-12-31 | 2024-03-08 | 10-K | 24-028326 |
| 37 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 38,511,715 | 2026-03-02 | 2026-04-29 | 10-K/A | 26-191496 |
| 38 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 34,381,125 | 2025-03-01 | 2025-03-10 | 10-K | 25-036349 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.